Stasi Kalliopi, Nagel Dalia, Yang Xiaoyan, Wang Rong-Fang, Ren Lizhen, Podos Steven M, Mittag Thom, Danias John
Department of Ophthalmology, Mt. Sinai School of Medicine, New York, New York 10029, USA.
Invest Ophthalmol Vis Sci. 2006 Mar;47(3):1024-9. doi: 10.1167/iovs.05-0830.
Complement has been implicated in the pathogenesis of neurodegenerative diseases. The purpose of this study was to investigate whether complement activation is part of the pathogenesis of retinal ganglion cell (RGC) loss in glaucoma.
mRNA and protein was extracted from the retina and brain of DBA/2 and C57/BL6 mice and subjected to RT-PCR and immunoblot analysis, respectively. In addition, eyes from the same mouse strains were subjected to immunohistochemistry with antibodies specific to complement component 1q (C1q). Eyes from monkeys with unilateral experimental glaucoma were also subjected to immunohistochemical analysis, as were eyes from human subjects with or without glaucoma.
C1q mRNA and C1q protein were found to be upregulated in the retina of glaucomatous DBA/2 mice. Upregulation of C1q preceded the time of extensive RGC death and increased with increasing age to 15 months in the retina, but not in the brain. No age-related C1q upregulation was detected in the reference mouse strain (C57BL/6), which develops significant nonglaucomatous RGC loss toward the end of the same time frame. C1q upregulation was also detected in laser-induced glaucomatous monkey eyes and in some (but not all) eyes of patients with glaucoma. C1q upregulation was localized to the Müller cells within the retina and in the area of the inner limiting membrane.
Complement expression is upregulated in the retina of two commonly used glaucoma models (in the DBA/2 mouse and the monkey) and in some human glaucomatous eyes. The timing of this upregulation suggests that complement activation plays a significant role in the pathogenesis of glaucoma.
补体已被认为与神经退行性疾病的发病机制有关。本研究的目的是调查补体激活是否是青光眼视网膜神经节细胞(RGC)丢失发病机制的一部分。
分别从DBA/2和C57/BL6小鼠的视网膜和大脑中提取mRNA和蛋白质,分别进行逆转录聚合酶链反应(RT-PCR)和免疫印迹分析。此外,对来自相同小鼠品系的眼睛用补体成分1q(C1q)特异性抗体进行免疫组织化学分析。对单侧实验性青光眼的猴子眼睛以及有或没有青光眼的人类受试者的眼睛也进行免疫组织化学分析。
在青光眼DBA/2小鼠的视网膜中发现C1q mRNA和C1q蛋白上调。C1q的上调先于广泛的RGC死亡时间,并随着年龄增长至15个月在视网膜中增加,但在大脑中没有增加。在参考小鼠品系(C57BL/6)中未检测到与年龄相关的C1q上调,该品系在同一时间框架结束时出现明显的非青光眼性RGC丢失。在激光诱导的青光眼猴子眼睛以及一些(但不是所有)青光眼患者的眼睛中也检测到C1q上调。C1q上调定位于视网膜内的 Müller 细胞和内界膜区域。
在两种常用的青光眼模型(DBA/2小鼠和猴子)的视网膜以及一些人类青光眼眼中,补体表达上调。这种上调的时间表明补体激活在青光眼的发病机制中起重要作用。